Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications

Clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS)

Accuray Incorporated announced that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform in the treatment of neurological indications with non-invasive radiosurgery. The data highlight the benefits experienced by neurosurgeons for more than two decades, including the ability to effectively and efficiently deliver radiation in single and multi-fraction sessions, treat benign and functional cases, primary brain and spine tumors and metastases, as well as previously irradiated tumors.

More information

Details

Rte de la Longeraie 9, 1110 Morges, Switzerland

Accuray Europe

Associated Trend items

Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions

Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced today they are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus' artificial intelligence (AI)-driven autocontouring algorithms - enabling automated contouring to further streamline the treatment planning process*.

The companies expect an integrated offering to be made available beginning in 2023. Changes in tumor size, shape and location, or in the position of organs and other healthy tissue due to weight gain or loss during the course of radiation therapy, may require adaptation of the treatment plan to ensure the radiation dose remains targeted on the tumor while avoiding nearb...

More information

TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients' Long-term Heart and Lung Functionality

Phase III, randomized controlled trial results highlight patient reported outcomes at 10 years' follow-up

Accuray Incorporated announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer. An analysis of patient reported outcomes showed 1...

More information

Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022

We announced that our commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers

According to the IMV ServiceTrak™ Radiation Oncology 2022 report, Accuray achieved the highest score in the industry in Overall Service Performance and was recognized for Best Service in Radiation Oncology. The IMV report includes feedback on radiation therapy technologies used in treating cancer patients in the U.S. and specifically, survey respondents with hands-on exp...

More information

Products associated

robotic assisted radiosurgery linear particle accelerator

CyberKnife® S7™

Compare

Remove all

Compare up to 10 products